Sandeep Kulkarni shares a framework from his chairman, Clay Siegall: a biotech can fail, get acquired after short-term success, get acquired after long-term success, or achieve rare 'escape velocity' to stay independent. This pragmatic view frames acquisition not as a lesser option but as a primary successful outcome for most.

When aiming for a billion-dollar outcome, a 10-20% valuation difference in early funding rounds becomes negligible. The priority should be securing a long runway with as much capital as possible when it's available, as this enables the execution required to reach a massive exit.

Mergers and acquisitions are more than just exits for private biotech companies. They are the primary mechanism for returning capital to venture capitalists and LPs, who then reinvest those funds back into the ecosystem, fueling the next generation of innovative startups.

While biotech is seeing renewed investor interest after being 'left for dead,' its culture differs from mainstream tech. Instead of chasing unicorn-or-bust 'power law' outcomes, the biotech community often prioritizes more frequent, smaller exits in the low billions, creating a pattern of 'base hits' and serial entrepreneurship.

While a challenging fundraising market seems negative, it forces startups to operate with discipline. Unlike in frothy markets where companies expand based on hype, the current climate rewards tangible results. This compels a lean structure focused on high-value projects, creating a healthier long-term business model.

Contrary to the 'raise as much as you can' mentality, taking smaller, more frequent funding rounds is strategically better. This approach allows for regular valuation markups, improves employee stock option value, maintains momentum, and avoids the pressure of an unattainably high valuation.

While first-time founders often optimize for the highest valuation, experienced entrepreneurs know this is a trap. They deliberately raise at a reasonable price, even if a higher one is available. This preserves strategic flexibility, makes future fundraising less perilous, and keeps options open—which is more valuable than a vanity valuation.

Ron Najafi advises founders to accept investment when it's offered rather than over-negotiating valuation. The security of having capital on hand to navigate unforeseen challenges like clinical study hiccups is more critical for long-term survival than a marginal valuation increase.

While biotech cannot easily replicate tech's rapid iteration cycles due to high costs and long feedback loops, it can adopt the capital efficiency model of tech seed investing. The strategy is to kill flawed projects quickly and cheaply, ensuring that when you lose, you lose small.